Roivant Sciences (ROIV) Cash & Equivalents (2021 - 2026)

Roivant Sciences (ROIV) has reported Cash & Equivalents for 6 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 0.81% year-over-year to $1.2 billion; the trailing twelve-month figure through Jun 2026 stood at $1.2 billion (up 0.81% YoY), and the FY2026 full-year result was $1.4 billion, down 47.73% from the prior year.
• Cash & Equivalents eased to $1.2 billion in Q2 2026 per ROIV's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $6.7 billion in Q4 2023 and bottomed at $1.2 billion in Q3 2025.
• Historically, Cash & Equivalents has averaged $2.4 billion across 5 years, with a median of $1.6 billion in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents soared 338.64% in 2023, then plunged 78.27% in 2025.
• Over 5 years, Cash & Equivalents stood at $1.5 billion in 2022, then surged by 338.64% to $6.7 billion in 2023, then plunged by 70.29% to $2.0 billion in 2024, then slipped by 25.74% to $1.5 billion in 2025, then fell by 15.55% to $1.2 billion in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.2 billion, $1.4 billion, and $1.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.